Outpatient treatment of chronic obstructive pulmonary disease: Comparisons with asthma

Journal of Allergy and Clinical Immunology

Volumn 114, Issue 4, 2004, Pages 715-724

  Sutherland, E Rand ^a,b  

^a Natl Jewish Med Res Ctr Univ C   (United States)

^b CO 80206 ^*  (United States)

Author keywords

asthma; Chronic obstructive pulmonary disease; therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHYLXANTHINE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; SALBUTAMOL SULFATE; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; ZAFIRLUKAST;

AIRWAY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CATARACT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG RECEPTOR BINDING; DYSPHONIA; EMPHYSEMA; FORCED EXPIRATORY VOLUME; FRACTURE; HEALTH CARE; HEALTH CARE MANAGEMENT; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNIZATION; INFECTION; INFLAMMATION; LUNG FUNCTION; LUNG PARENCHYMA; LUNG SURGERY; MAINTENANCE THERAPY; MORTALITY; MUSCLE WEAKNESS; NONHUMAN; OSTEOLYSIS; OUTPATIENT CARE; OXYGEN SUPPLY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMOKING; SMOKING CESSATION; SPIROMETRY; THRUSH; TREATMENT OUTCOME; VACCINATION;

EID: 4944258181     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.07.044     Document Type: Review

References (112)

1. C. Fletcher, and R. Peto The natural history of chronic airflow obstruction BMJ 1 1977 1645 1648
2. S. Eriksson Studies in alpha 1-antitrypsin deficiency Acta Med Scand Suppl 432 1965 1 85
3. D.P. Tashkin, M.D. Altose, J.E. Connett, R.E. Kanner, W.W. Lee, and R.A. Wise Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group Am J Respir Crit Care Med 153 1996 1802 1811
4. R. Perez-Padilla, J. Regalado, S. Vedal, P. Pare, R. Chapela, and R. Sansores Exposure to biomass smoke and chronic airway disease in Mexican women Am J Respir Crit Care Med 154 1996 701 706
5. E.R. Sutherland, and R.J. Martin Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma J Allergy Clin Immunol 112 2003 819 827
6. M. Saetta, A. Di Stefano, P. Maestrelli, A. Ferraresso, R. Drigo, and A. Potena Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis Am Rev Respir Dis 147 1993 301 306
7. M. Saetta, A. Di Stefano, G. Turato, F.M. Facchini, L. Corbino, and C.E. Mapp CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 822 826
8. R. Finkelstein, R.S. Fraser, H. Ghezzo, and M.G. Cosio Alveolar inflammation and its relation to emphysema in smokers Am J Respir Crit Care Med 152 1995 1666 1672
9. M. Saetta, A. Di Stefano, P. Maestrelli, G. Turato, M.P. Ruggieri, and P.G. Calcagni Airway eosinophilia in chronic bronchitis during exacerbations Am J Respir Crit Care Med 150 1994 1646 1652
10. D. Stanescu, A. Sanna, C. Veriter, S. Kostianev, P.G. Calcagni, and L.M. Fabbri Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils Thorax 51 1996 267 271
11. A. Churg, R.D. Wang, H. Tai, X. Wang, C. Xie, and J. Dai Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release Am J Respir Crit Care Med 167 2003 1083 1089
12. A. Churg, K. Zay, S. Shay, C. Xie, S.D. Shapiro, and R. Hendricks Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice Am J Respir Cell Mol Biol 27 2002 368 374
13. J.C. Hogg, P.T. Macklem, and W.M. Thurlbeck Site and nature of airway obstruction in chronic obstructive lung disease N Engl J Med 278 1968 1355 1360
14. M.G. Cosio, and A. Guerassimov Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma Am J Respir Crit Care Med 160 suppl 1999 S21 S25
15. J.C. Hogg, F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, and L. Buzatu The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653
16. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 suppl 1995 S77 S121
17. J.C. Hogg, and R.M. Senior Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema Thorax 57 2002 830 834
18. N.R. Anthonisen, J.E. Connett, and R.P. Murray Smoking and lung function of Lung Health Study participants after 11 years Am J Respir Crit Care Med 166 2002 675 679
19. L.M. Fabbri, and S.S. Hurd Global strategy for the diagnosis, management and prevention of COPD: 2003 update Eur Respir J 22 2003 1 2
20. American Thoracic Society Lung function testing: selection of reference values and interpretative strategies Am Rev Respir Dis 144 1991 1202 1218
21. P.M. Calverley, P.S. Burge, S. Spencer, J.A. Anderson, and P.W. Jones Bronchodilator reversibility testing in chronic obstructive pulmonary disease Thorax 58 2003 659 664
22. D.P. Tashkin, M.D. Altose, E.R. Bleecker, J.E. Connett, R.E. Kanner, and W.W. Lee The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group Am Rev Respir Dis 145 1992 301 310
23. Standards of Care Committee of the British Thoracic Society BTS guidelines for the management of chronic obstructive pulmonary disease Thorax 52 suppl 1997 S1 S28
24. D.E. O'Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D. Marciniuk, and M. Balter Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003 Can Respir J 10 suppl A 2003 11A 65A
25. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
26. D.M. Mannino, A.S. Buist, T.L. Petty, P.L. Enright, and S.C. Redd Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study Thorax 58 2003 388 393
27. E.R. Sutherland, and R.M. Cherniack Management of chronic obstructive pulmonary disease N Engl J Med 350 2004 2689 2697
28. J. Buffels, J. Degryse, J. Heyrman, and M. Decramer Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study Chest 125 2004 1394 1399
29. 1 JAMA 272 1994 1497 1505
30. N.A. Rigotti Treatment of tobacco use and dependence N Engl J Med 346 2002 506 512
31. K.L. Nichol, K.L. Margolis, J. Wuorenma, and T. Von Sternberg The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community N Engl J Med 331 1994 778 784
32. K.L. Nichol, J. Nordin, J. Mullooly, R. Lask, K. Fillbrandt, and M. Iwane Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly N Engl J Med 348 2003 1322 1332
33. B.G. Higgins, R.M. Powell, S. Cooper, and A.E. Tattersfield Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis Eur Respir J 4 1991 415 420
34. R. Dahl, L.A. Greefhorst, D. Nowak, V. Nonikov, A.M. Byrne, and M.H. Thomson Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778 784
35. S.I. Rennard, W. Anderson, R. ZuWallack, J. Broughton, W. Bailey, and M. Friedman Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087 1092
36. R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, and P. Magyar Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur Respir J 19 2002 936 943
37. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, P.G. San, and R.L. ZuWallack A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224
38. M.J. Belman, W.C. Botnick, and J.W. Shin Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 153 1996 967 975
39. D.E. O'Donnell, M. Lam, and K.A. Webb Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 1999 542 549
40. D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, and B. Aguilaniu Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur Respir J 23 2004 832 840
41. Combivent Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial Chest 105 1994 1411 1419
42. N.J. Gross, T.L. Petty, M. Friedman, M.S. Skorodin, G.W. Silvers, and J.F. Donohue Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study Am Rev Respir Dis 139 1989 1188 1191
43. F.S. Ram, and P. Sestini Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis Thorax 58 2003 580 584
44. G.R. Petrie, and K.N. Palmer Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma BMJ 1 1975 430 432
45. M. Wadbo, C.G. Lofdahl, K. Larsson, B.E. Skoogh, G. Tornling, and E. Arwestrom Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Eur Respir J 20 2002 1138 1146
46. J.A. van Noord, D.R. de Munck, T.A. Bantje, W.C. Hop, M.L. Akveld, and A.M. Bommer Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium Eur Respir J 15 2000 878 885
47. M. Cazzola, F.D. Marco, P. Santus, B. Boveri, M. Verga, and M.G. Matera The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD Pulm Pharmacol Ther 17 2004 35 39
48. D. Cook, G. Guyatt, E. Wong, R. Goldstein, M. Bedard, and P. Austin Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 85 90
49. Expert Panel Report 2 - Guidelines for the diagnosis and management of asthma. Publication no. 97-4051 1997 National Institutes of Health, National Heart Lung and Blood Institute Bethesda (MD)
50. E.Y. Derom, R.A. Pauwels, and M.E. Van der Straeten The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours J Allergy Clin Immunol 89 1992 811 815
51. S.D. Anderson, L.T. Rodwell, J. Du Toit, and I.H. Young Duration of protection by inhaled salmeterol in exercise-induced asthma Chest 100 1991 1254 1260
52. A. Patessio, A. Podda, M. Carone, N. Trombetta, and C.F. Donner Protective effect and duration of action of formoterol aerosol on exercise-induced asthma Eur Respir J 4 1991 296 300
53. E.H. Ramsdale, J. Otis, P.A. Kline, L.S. Gontovnick, F.E. Hargreave, and P.M. O'Byrne Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol Am Rev Respir Dis 143 1991 998 1001
54. F.E. Simons, N.R. Soni, W.T. Watson, and A.B. Becker Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma J Allergy Clin Immunol 90 1992 840 846
55. O.P. Twentyman, J.P. Finnerty, A. Harris, J. Palmer, and S.T. Holgate Protection against allergen-induced asthma by salmeterol Lancet 336 1990 1338 1342
56. A.A. Verberne, C. Frost, R.J. Roorda, H. van der Laag, and K.F. Kerrebijn One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group Am J Respir Crit Care Med 156 1997 688 695
57. D. Bouros, N. Bachlitzanakis, J. Kottakis, P. Pfister, V. Polychronopoulos, and E. Papadakis Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma Eur Respir J 14 1999 627 632
58. A.P. Greening, P.W. Ind, M. Northfield, and G. Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids Lancet 344 1994 219 224
59. A. Woolcock, B. Lundback, N. Ringdal, and L.A. Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Respir Crit Care Med 153 1996 1481 1488
60. R.F. Lemanske Jr., C.A. Sorkness, E.A. Mauger, S.C. Lazarus, H.A. Boushey, and J.V. Fahy Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial JAMA 285 2001 2594 2603
61. B.F. Luisi, W.X. Xu, Z. Otwinowski, L.P. Freedman, K.R. Yamamoto, and P.B. Sigler Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA Nature 352 1991 497 505
62. P.J. Barnes, A.P. Greening, and G.K. Crompton Glucocorticoid resistance in asthma Am J Respir Crit Care Med 152 suppl 1995 S125 S140
63. M.I. Diamond, J.N. Miner, S.K. Yoshinaga, and K.R. Yamamoto Transcription factor interactions: selectors of positive or negative regulation from a single DNA element Science 249 1990 1266 1272
64. A. Waage, and O. Bakke Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes Immunology 63 1988 299 302
65. N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg, and M. Karin Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis Science 270 1995 286 290
66. J.W. Wilson, R. Djukanovic, P.H. Howarth, and S.T. Holgate Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma Am J Respir Crit Care Med 149 1994 86 90
67. L.A. Laitinen, A. Laitinen, and T. Haahtela A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial J Allergy Clin Immunol 90 1992 32 42
68. P.J. Barnes Efficacy of inhaled corticosteroids in asthma J Allergy Clin Immunol 102 1998 531 538
69. J.G. Donahue, S.T. Weiss, J.M. Livingston, M.A. Goetsch, D.K. Greineder, and R. Platt Inhaled steroids and the risk of hospitalization for asthma JAMA 277 1997 887 891
70. S. Suissa, P. Ernst, S. Benayoun, M. Baltzan, and B. Cai Low-dose inhaled corticosteroids and the prevention of death from asthma N Engl J Med 343 2000 332 336
71. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 2004 731 733
72. R.A. Pauwels, C.G. Lofdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, and N.B. Pride Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948 1953
73. J. Vestbo, T. Sorensen, P. Lange, A. Brix, P. Torre, and K. Viskum Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial Lancet 353 1999 1819 1823
74. P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
75. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902 1909
76. S. Spencer, P.M. Calverley, P. Sherwood Burge, and P.W. Jones Health status deterioration in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 122 128
77. R. Chaudhuri, E. Livingston, A.D. McMahon, L. Thomson, W. Borland, and N.C. Thomson Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma Am J Respir Crit Care Med 168 2003 1308 1311
78. G.C. Donaldson, T.A. Seemungal, A. Bhowmik, and J.A. Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
79. E. Israel, T.R. Banerjee, G.M. Fitzmaurice, T.V. Kotlov, K. LaHive, and M.S. LeBoff Effects of inhaled glucocorticoids on bone density in premenopausal women N Engl J Med 345 2001 941 947
80. N.J. Shaw, and A.T. Edmunds Inhaled beclomethasone and oral candidiasis Arch Dis Child 61 1986 788 790
81. J.H. Toogood, B. Jennings, R.W. Greenway, and L. Chuang Candidiasis and dysphonia complicating beclomethasone treatment of asthma J Allergy Clin Immunol 65 1980 145 153
82. A.K. Kamada, S.J. Szefler, R.J. Martin, H.A. Boushey, V.M. Chinchilli, and J.M. Drazen Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network Am J Respir Crit Care Med 153 1996 1739 1748
83. P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919
84. P.M. Calverley, R.A. Pauwels, J. Vestbo, P.C. Jones, N.B. Pride, and A. Gulsvik Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
85. N.A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, and S. Davis The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD Chest 124 2003 834 843
86. L.J. Walsh, C.A. Wong, J. Oborne, S. Cooper, S.A. Lewis, and M. Pringle Adverse effects of oral corticosteroids in relation to dose in patients with lung disease Thorax 56 2001 279 284
87. P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, and J.A. Anderson Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study Thorax 58 2003 654 658
88. D. Spina, L.J. Landells, and C.P. Page The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs Clin Exp Allergy 28 suppl 3 1998 24 34
89. P.J. Barnes, and R.A. Pauwels Theophylline in the management of asthma: time for reappraisal? Eur Respir J 7 1994 579 591
90. P. Sullivan, S. Bekir, Z. Jaffar, C. Page, P. Jeffery, and J. Costello Anti-inflammatory effects of low-dose oral theophylline in atopic asthma Lancet 343 1994 1006 1008
91. M. Kraft, J.A. Torvik, J.B. Trudeau, S.E. Wenzel, and R.J. Martin Theophylline: potential antiinflammatory effects in nocturnal asthma J Allergy Clin Immunol 97 1996 1242 1246
92. S. Crescioli, A. Dal Carobbo, P. Maestrelli, P. Boschetto, T. Santagada, and V.W. Steinijans Controlled-release theophylline inhibits early morning airway obstruction and hyperresponsiveness in asthmatic subjects Ann Allergy Asthma Immunol 77 1996 106 110
93. C.P. Page, T. Cotter, S. Kilfeather, P. Sullivan, D. Spina, and J.F. Costello Effect of chronic theophylline treatment on the methacholine dose- response curve in allergic asthmatic subjects Eur Respir J 12 1998 24 29
94. S.E. McKay, C.A. Howie, A.H. Thomson, B. Whiting, and G.J. Addis Value of theophylline treatment in patients handicapped by chronic obstructive lung disease Thorax 48 1993 227 232
95. R.L. ZuWallack, D.A. Mahler, D. Reilly, N. Church, A. Emmett, and K. Rickard Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 2001 1661 1670
96. C.H. Compton, J. Gubb, R. Nieman, J. Edelson, O. Amit, and A. Bakst Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study Lancet 358 2001 265 270
97. I.E. Zuhlke, F. Kanniess, K. Richter, D. Nielsen-Gode, S. Bohme, and R.A. Jorres Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD Eur Respir J 22 2003 926 930
98. M. Cazzola, B. Boveri, P. Carlucci, P. Santus, F. DiMarco, and S. Centanni Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist Pulm Pharmacol Ther 13 2000 301 305
99. Y. Lacasse, E. Wong, G.H. Guyatt, D. King, D.J. Cook, and R.S. Goldstein Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease Lancet 348 1996 1115 1119
100. T.L. Griffiths, M.L. Burr, I.A. Campbell, V. Lewis-Jenkins, J. Mullins, and K. Shiels Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial Lancet 355 2000 362 368
101. British Thoracic Society standards of care subcommittee on pulmonary rehabilitation BTS statement: pulmonary rehabilitation Thorax 56 2001 827 834
102. K. Gray-Donald, L. Gibbons, S.H. Shapiro, P.T. Macklem, and J.G. Martin Nutritional status and mortality in chronic obstructive pulmonary disease Am J Respir Crit Care Med 153 1996 961 966
103. I.M. Ferreira, D. Brooks, Y. Lacasse, R.S. Goldstein, and J. White Nutritional supplementation for stable chronic obstructive pulmonary disease Cochrane Database of Systematic Reviews 1 2003
104. Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema Lancet 1 1981 681 686
105. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial Ann Intern Med 93 1980 391 398
106. M. Emtner, J. Porszasz, M. Burns, A. Somfay, and R. Casaburi Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients Am J Respir Crit Care Med 168 2003 1034 1042
107. D.J. Meecham Jones, E.A. Paul, P.W. Jones, and J.A. Wedzicha Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD Am J Respir Crit Care Med 152 1995 538 544
108. F.J. O'Donoghue, P.G. Catcheside, A.S. Jordan, A.D. Bersten, and R.D. McEvoy Effect of CPAP on intrinsic PEEP, inspiratory effort, and lung volume in severe stable COPD Thorax 57 2002 533 539
109. E. Clini, C. Sturani, A. Rossi, S. Viaggi, A. Corrado, and C.F. Donner The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients Eur Respir J 20 2002 529 538
110. A. Fishman, F. Martinez, K. Naunheim, S. Piantadosi, R. Wise, and A. Ries A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema N Engl J Med 348 2003 2059 2073
111. National Emphysema Treatment Trial Research Group Patients at high risk of death after lung-volume-reduction surgery N Engl J Med 345 2001 1075 1083
112. S.M. Arcasoy, and R.M. Kotloff Lung transplantation N Engl J Med 340 1999 1081 1091